ArticleBioengineering & translational medicine2018
Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques.
Article in Bioengineering & translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- Article
- Hydrogels in Veterinary Vaccine Development: Types, Mechanisms, and Applications.Gels (Basel, Switzerland) · 2025Review
- Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.Drug delivery and translational research · 2025Article
- Drug delivery to and through the skin.Drug delivery and translational research · 2024Review
- 3D Printing of Biodegradable Polymeric Microneedles for Transdermal Drug Delivery Applications.Pharmaceutics · 2024Article
- Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.Vaccine · 2023Article
- Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development.Yonsei medical journal · 2022Review
- Evaluation of efficacy and safety of intradermal delivery of vaccines through microneedle(s) in human beings: a protocol for a systematic review.Systematic reviews · 2022Article
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study.PLOS global public health · 2022Article
- Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.Pharmaceutics · 2021Review
- Efficient Drug Delivery into Skin Using a Biphasic Dissolvable Microneedle Patch with Water-Insoluble Backing.Advanced functional materials · 2021Article
- Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks.Vaccines · 2021Article
- Microarray patches enable the development of skin-targeted vaccines against COVID-19.Advanced drug delivery reviews · 2021Review
- Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.Expert opinion on drug delivery · 2021Review
- Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021Article
- Microneedle for transdermal drug delivery: current trends and fabrication.Journal of pharmaceutical investigation · 2021Review
- Article
- Characterization of Hepatitis B Surface Antigen Loaded Polylactic Acid-Based Microneedle and Its Dermal Safety Profile.Pharmaceutics · 2020Article
- The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.Expert review of vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Chronic Hepatitis B virus infection remains a major global public health problem, accounting for about 887,000 deaths in 2015. Perinatal and early childhood infections are strongly associated with developing chronic hepatitis B. Adding a birth dose of the hepatitis B vaccine (HepB BD) to routine childhood vaccination can prevent over 85% of these infections. However, HepB BD coverage remains low in many global regions, with shortages of birth attendants trained to vaccinate and limited HepB BD supply at birth. To address the challenges, we developed coated metal microneedle patches (cMNPs) and dissolvable microneedle patches (dMNPs) that deliver adjuvant-free hepatitis B vaccine to the skin in a simple-to-administer manner. The dMNP contains micron-scale, solid needles encapsulating vaccine antigen and dissolve in the skin, generating no sharps waste. We delivered HepB BD via cMNP to BALB/c mice and via dMNP to both mice and rhesus macaques. Both cMNP and dMNP were immunogenic, generating hepatitis B surface antibody levels similar to human seroprotection. Biomechanical analysis showed that at high forces the microneedles failed mechanically by yielding but microneedles partially blunted by axial compression were still able to penetrate skin. Overall, this study indicates that with further development, dMNPs could offer a method of vaccination to increase HepB BD access and reduce needle waste in developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.